BofA upgraded Fate Therapeutics (FATE) to Neutral from Underperform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Stifel ‘impressed’ with results for Fate Therapeutics’ first FT819 LN patient
- Fate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial
- Fate Therapeutics presents 6-month data on first lupus patient
- Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges
- Fate Therapeutics Unveils Q3 2024 Financial Highlights